Cardiovascular diseases and the heart–gut cross talk DOI Creative Commons
Snehali Majumder, Rohan Makwana, Varun Shetty

и другие.

Indian Heart Journal, Год журнала: 2023, Номер 76(2), С. 94 - 100

Опубликована: Дек. 7, 2023

The purpose of this narrative review is to provide a comprehensive overview current research on heart-gut cross talk and its implications for cardiovascular disease. To uncover relevant preclinical clinical examining talk, thorough literature search was undertaken utilising electronic databases. chosen publications were critically examined, major findings synthesised offer perspective the subject. We want synthesise most recent study findings, explain underlying mechanisms, potential treatment techniques. By exploring bidirectional connection between heart gut, we shed light novel future options prevention diseases. an exciting field with Understanding complex gastrointestinal tract may lead development therapeutic targets therapies management Future should concentrate identifying specific processes driving crosstalk as well assessing efficacy targeting gut microbiota gut-brain axis in improving outcomes.

Язык: Английский

SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism DOI Open Access
Milton Packer

Nature Reviews Cardiology, Год журнала: 2023, Номер 20(7), С. 443 - 462

Опубликована: Янв. 6, 2023

Язык: Английский

Процитировано

96

Metabolic Flexibility of the Heart: The Role of Fatty Acid Metabolism in Health, Heart Failure, and Cardiometabolic Diseases DOI Open Access
Virginia Actis Dato, Stephan Lange, Yoshitake Cho

и другие.

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(2), С. 1211 - 1211

Опубликована: Янв. 19, 2024

This comprehensive review explores the critical role of fatty acid (FA) metabolism in cardiac diseases, particularly heart failure (HF), and implications for therapeutic strategies. The heart’s reliance on ATP, primarily sourced from mitochondrial oxidative metabolism, underscores significance metabolic flexibility, with oxidation (FAO) being a dominant source. In HF, shifts occur an altered FA uptake FAO, impacting function contributing to disease progression. Conditions like obesity diabetes also lead disturbances, resulting cardiomyopathy marked by over-reliance dysfunction, lipotoxicity. Therapeutic approaches targeting diseases have evolved, focusing inhibiting or stimulating FAO optimize energetics. Strategies include using CPT1A inhibitors, PPARα agonists, enhancing biogenesis function. However, effectiveness varies, reflecting complexity remodeling HF. Hence, treatment strategies should be individualized, considering that energy is intricate tightly regulated. aim overall function, recognizing pivotal FAs need further research develop effective therapies, promising new improve

Язык: Английский

Процитировано

18

Aldose reductase inhibition alleviates diabetic cardiomyopathy and is associated with a decrease in myocardial fatty acid oxidation DOI Creative Commons
Keshav Gopal, Qutuba G. Karwi, Seyed Amirhossein Tabatabaei Dakhili

и другие.

Cardiovascular Diabetology, Год журнала: 2023, Номер 22(1)

Опубликована: Март 28, 2023

Abstract Background Cardiovascular diseases, including diabetic cardiomyopathy, are major causes of death in people with type 2 diabetes. Aldose reductase activity is enhanced hyperglycemic conditions, leading to altered cardiac energy metabolism and deterioration function adverse remodeling. Because disturbances can promote inefficiency, we hypothesized that aldose inhibition may mitigate cardiomyopathy via normalization metabolism. Methods Male C57BL/6J mice (8-week-old) were subjected experimental diabetes/diabetic (high-fat diet [60% kcal from lard] for 10 weeks a single intraperitoneal injection streptozotocin (75 mg/kg) at 4 weeks), following which animals randomized treatment either vehicle or AT-001, next-generation inhibitor (40 mg/kg/day) 3 weeks. At study completion, hearts perfused the isolated working mode assess Results by AT-001 improved diastolic efficiency This attenuation was associated decreased myocardial fatty acid oxidation rates (1.15 ± 0.19 vs 0.5 0.1 µmol min −1 g dry wt presence insulin) but no change glucose compared control group. In addition, fibrosis hypertrophy also mitigated cardiomyopathy. Conclusions Inhibiting ameliorates dysfunction diabetes, be due decline oxidation, indicating novel approach alleviate patients

Язык: Английский

Процитировано

23

Double-side role of short chain fatty acids on host health via the gut-organ axes DOI Creative Commons
Yanan Gao, Qianqian Yao, Lu Meng

и другие.

Animal nutrition, Год журнала: 2024, Номер 18, С. 322 - 339

Опубликована: Май 17, 2024

Short chain fatty acids (SCFA) exist in dietary foods and are produced by the fermentation of gut microbiota, considered an important element for regulating host health. Through blood circulation, SCFA obtained from have impact on intestinal health as well vital organs host. It has been recognized that is "vital organ" As microbial metabolites, could create "axis" connecting to other organs. Therefore, "gut-organ axes" become a focus research recent years analyze organism In this review, we summarized sources, absorption properties, function both peripheral tissues (brain, kidney, liver, lung, bone cardiovascular) way axes". exert beneficial pathological role various ways, which effects more pronounced. addition, reflected preventive therapeutic effects. More importantly, mechanisms behinds provided insight into SCFA, assisting development novel strategies maintaining

Язык: Английский

Процитировано

7

Short-Chain Fatty Acids in Gut–Heart Axis: Their Role in the Pathology of Heart Failure DOI Open Access

Midori Yukino-Iwashita,

Yuji Nagatomo, Akane Kawai

и другие.

Journal of Personalized Medicine, Год журнала: 2022, Номер 12(11), С. 1805 - 1805

Опубликована: Ноя. 1, 2022

Heart failure (HF) is a syndrome with global clinical and socioeconomic burden worldwide owing to its poor prognosis. Accumulating evidence has implicated the possible contribution of gut microbiota-derived metabolites, short-chain fatty acids (SCFAs), on pathology variety diseases. The changes SCFA concentration were reported be observed in various cardiovascular diseases including HF experimental animals humans. causes hypoperfusion and/or congestion gut, which may lead lowered production SCFAs, possibly through pathological microenvironment microbiota composition. Recent studies suggest that SCFAs play significant role HF, an agonistic effect G-protein-coupled receptors, histone deacetylases (HDACs) inhibition, restoration mitochondrial function, amelioration cardiac inflammatory response, utilization as energy source, remote attributable protective other organs. Collectively, might key mediator gut–heart axis. However, these mechanisms have not been entirely clarified need further investigation.

Язык: Английский

Процитировано

27

The Anti-Inflammatory and Antioxidant Impact of Dietary Fatty Acids in Cardiovascular Protection in Older Adults May Be Related to Vitamin C Intake DOI Creative Commons
Anna Gawron-Skarbek, Agnieszka Guligowska, Anna Prymont-Przymińska

и другие.

Antioxidants, Год журнала: 2023, Номер 12(2), С. 267 - 267

Опубликована: Янв. 25, 2023

Polyunsaturated fatty acids, such as eicosapentaenoic acid (EPA), docosahexaenoic (DHA), α-linolenic (ALA), or linoleic (LA), have a particular role in counteracting cardiovascular diseases. They may regulate antioxidant potential and inflammatory reactions. Little is known whether other saturated acids (e.g., short-chain (SCFA) butyric caproic acid) monounsaturated be involved the level of Vitamin C intake affect these processes. The purpose this study was to assess impact on plasma salivary total capacity (TAC), inflammation marker C-reactive protein (CRP). Eighty older adults (60-79 years old) were divided into two groups with high (n = 39) low 41) intake. In group SCFA, ALA, LA positively correlated TAC indices, intake, decreased subjects higher SCFA Salivary CRP negatively corresponded EPA, DHA whole (p < 0.05 for all). Fatty influence CRP.

Язык: Английский

Процитировано

15

Gut Failure: A Review of the Pathophysiology and Therapeutic Potentials in the Gut–Heart Axis DOI Open Access
Dionysis Matsiras, Sofia Bezati, Ioannis Ventoulis

и другие.

Journal of Clinical Medicine, Год журнала: 2023, Номер 12(7), С. 2567 - 2567

Опубликована: Март 29, 2023

Despite considerable advances in the field, heart failure (HF) still poses a significant disease burden among affected individuals since it continues to cause high morbidity and mortality rates. Inflammation is considered play key role progression, but exact underlying pathophysiological mechanisms involved have not yet been fully elucidated. The gut, as potential source of inflammation, could feasibly explain state low-grade inflammation seen patients with chronic HF. Several derangements composition microbiota population, coupled an imbalance between favorable harmful metabolites followed by gut barrier disruption eventually bacterial translocation, contribute cardiac dysfunction aggravate On other hand, HF-associated congestion hypoperfusion alters intestinal function, thereby creating vicious cycle. Based on this evidence, novel pharmaceutical agents developed their therapeutic use has tested both animal human subjects. ultimate goal these efforts reverse aforementioned block cascade. This review summarizes gut-related causative pathways implicated HF pathophysiology, well associated interventions described literature.

Язык: Английский

Процитировано

14

Recent Advances in Microbiota-Associated Metabolites in Heart Failure DOI Creative Commons
Sepiso K. Masenga, Joreen P. Povia,

Propheria C. Lwiindi

и другие.

Biomedicines, Год журнала: 2023, Номер 11(8), С. 2313 - 2313

Опубликована: Авг. 21, 2023

Heart failure is a risk factor for adverse events such as sudden cardiac arrest, liver and kidney death. The gut microbiota its metabolites are directly linked to the pathogenesis of heart failure. As emerging studies have increased in literature on role specific development, this review highlights summarizes current evidence underlying mechanisms associated with We found that microbiota-derived short chain fatty acids, bile branched-chain amino tryptophan indole derivatives well trimethylamine-derived metabolite, trimethylamine N-oxide, play critical roles promoting through various mechanisms. Mainly, they modulate complex signaling pathways nuclear kappa-light-chain-enhancer activated B cells, Bcl-2 interacting protein 3, NLR Family Pyrin Domain Containing inflammasome, Protein kinase RNA-like endoplasmic reticulum kinase. also highlighted beneficial other cardiovascular metabolic diseases.

Язык: Английский

Процитировано

14

Gut-derived short-chain fatty acids bridge cardiac and systemic metabolism and immunity in heart failure DOI Open Access
Anzhu Wang, Qiang Li,

Zhuo Sun

и другие.

The Journal of Nutritional Biochemistry, Год журнала: 2023, Номер 120, С. 109370 - 109370

Опубликована: Май 26, 2023

Язык: Английский

Процитировано

11

2-[18F]Fluoropropionic Acid PET Imaging of Doxorubicin-Induced Cardiotoxicity DOI Creative Commons
Juan A. Azcona,

Anja Wacker,

Chulhee Lee

и другие.

Molecular Imaging and Biology, Год журнала: 2025, Номер 27(1), С. 109 - 119

Опубликована: Янв. 14, 2025

Treatment of pediatric cancers with doxorubicin is a common and predictable cause cardiomyopathy. Early diagnosis treatment-induced cardiotoxicity intervention are major determinants for the prevention advanced disease. The onset cardiomyopathies often accompanied by profound changes in lipid metabolism, including an enhanced uptake short-chain fatty acids (SCFA). Therefore, we explored utility 2-[18F]fluoropropionic acid ([18F]FPA), SCFA analog, as imaging biomarker cardiac injury mice exposed to doxorubicin. Cardiotoxicity dysfunction were induced 8-dose regimen (cumulative dose 24 mg/kg) administered over 14 days. effects exposure assessed measurement heart weights, left ventricular ejection fractions, blood troponin levels. Whole body [18F]FPA uptakes determined PET tissue gamma counting presence or absence AZD3965, pharmacological inhibitor monocarboxylate transporter 1 (MCT1). Radiation absorbed doses estimated using time-activity concentrations. Significantly higher was observed doxorubicin-treated animals. This remained constant from 30 120 min post-injection. Pharmacological inhibition MCT1-mediated transport AZD3965 selectively decreased tissues other than heart. Co-administration contrast diseased while reducing overall radioactivity. [18F]FPA, especially when co-administered new tool metabolism occurring response doxorubicin-induced cardiomyopathy PET.

Язык: Английский

Процитировано

0